SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries informs about company updates

22 Jun 2017 Evaluate

Pursuant to the requirements of Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, Sun Pharmaceutical Industries has informed about the details of the result of remote e-voting, postal ballot and poll conducted at the NCLT convened meeting of equity shareholders of Sun Pharmaceutical Industries held on June 20, 2017 at 10:15 a.m. IST at Sir Sayajirao Nagargruh, Akota, Vadodara- 390 020, Gujarat, for approval of the Scheme of Arrangement among Sun Pharma Medisales, Ranbaxy Drugs, Gufic Pharma, Vidyut Investments and the Company and their respective members and creditors along with the Scrutinizers Report.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Inds. Share Price

1847.30 12.90 (0.70%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×